Navigation Links
Mount Sinai leads unprecedented, NIH-supported attempt to discover rules for assembling human tissue
Date:9/23/2009

Researchers from Mount Sinai School of Medicine and two other academic institutions have received federal funding to systematically assemble functional human kidney tissue from tissue modeled on a computer. If successful, the researchwhich ties together several emerging technologies including virtual tissue modeling and nanofabricationcould lead to a more predictable way for researchers to engineer tissue outside the body and, consequently, to screen for new drugs.

To fund the project, called Dynamics Underlying Tissue Integrity, the National Institutes of Health (NIH) awarded a five-year, $6-million grant from its Transformative Research Projects (T-R01) program. T-R01 is a new program designed to support exceptionally innovative research initiatives whose anticipated outcomes have a major impact on broad, important problems in biomedical and/or behavioral research. T-R01 awardees42 total this yearreceive part of their funding from the American Recovery and Reinvestment Act.

The leader for this multi-principal investigator project, Ravi Iyengar, PhD, Director of the Experimental Therapeutics Institute (ETI) at Mount Sinai School of Medicine, said creation of a device for assembling tissue will require his team to solve a problem that has existed since pathologists first began examining human cells under microscopes.

"Pathologists typically characterize disease in patients by studying the shape of cells and tissues, and their diagnosis has always been largely empirical," said Dr. Iyengar, who is also Dorothy H. and Lewis Rosenstiel Professor and Chair, Pharmacology and Systems Therapeutics, and Professor of Oncological Sciences and Psychiatry, Mount Sinai School of Medicine. "No one knows why cell shapes change or the rules by which tissues are organized. We want to start getting a handle on this by studying the kidney, and doing that will require the collaboration of several different disciplines."

The scientists plan to focus on the podocyte, a specialized kidney cell that sits on the organ's basement membrane and controls the filtration of small molecules from proteins. A breach in this filtration barrier is a main cause of kidney disease that often occurs among patients with diabetes, HIV, and hypertension. African-Americans with hypertension are four times more likely than whites with hypertension to develop kidney disease, a condition that currently has no cure and can eventually necessitate dialysis.

According to Dr. Iyengar, discovering the tenets underlying tissue assembly, as he and colleagues plan to do here, and having a more predictable method for assembling tissues within a nanofabricated device, would have broad clinical impact. "Lack of engineered tissue devices in vitro, or outside the cell body, is a big impediment in testing new drugs," he said. "If this experiment works and we have a methodology to assemble these tissues within nanofabricated devices, this could become a very useful screening approach for discovery of new drugs for kidney disease."

"The efforts of Dr. Iyengar's team to better understand kidney function at the cellular level will aid therapeutics research," said Dennis S. Charney, MD, the Anne and Joel Ehrenkranz Dean of Mount Sinai School of Medicine and Executive Vice President for Academic Affairs at The Mount Sinai Medical Center. "Mount Sinai, whose infrastructure is designed to foster translational research, is tailor made for collaborative research projects such as this."

Much of the research will take place at the ETI, Mount Sinai's hub for developing new drugs and devices through integrating many facets of therapeutics research, and the NIGMS funded Systems Biology Center New York (SBCNY), which Dr. Iyengar also directs and which is also based at Mount Sinai. SBCNY researchers study at a systems level the molecular interactions within cells and their connection to the physiological function of tissues and organs.

"Dr. Iyengar has seized upon an extraordinary opportunitythe ability to harness systems biology to facilitate the development of new drugs and diagnostic tools," said Kenneth L. Davis, MD, President and CEO of The Mount Sinai Medical Center. "His work has the potential to create a new scientific paradigm."

The other principal investigators from Mount Sinai include John Cijiang He, MD, PhD, Associate Professor of Medicine and Nephrology and Assistant Professor of Pharmacology and Systems Therapeutics, and Susana Neves, PhD, Postdoctoral Fellow in the Department of Pharmacology and Systems Therapeutics.

Two other principal investigators sharing in the grant and lending their expertise are James C. Hone, PhD, of Columbia University, who will design and fabricate the micro- or nanometer-scale devices, and Leslie M. Loew, PhD, who pioneered the development of a computational modeling platform at the University of Connecticut Health Center called the Virtual Cell. Dr. Loew will develop computational models of how cells interact within kidney tissues.

These computational models, or virtual tissue, will form the basis for designing the device for recreating kidney function. The hope is to learn the rules of tissue organization as the team refines the device through testing the computer models and imaging the flow of cell signals within the reassembled tissue from both mouse and human cells.

Commenting on the grant, Francis S. Collins, MD, PhD, Director of the NIH, said the T-R01 program "is intended to support research that has the potential to transform the way we think about and conduct science, so the recipients represent an elite few with truly bold ideas. Competition for the awards was fierce, and standards very high."


'/>"/>

Contact: Mount Sinai Press Office
newsnow@mountsinai.org
212-241-9200
The Mount Sinai Hospital / Mount Sinai School of Medicine
Source:Eurekalert

Related medicine news :

1. Paramount Acquisition Corp. Announces Chem Rx Expansion into Albany, New York Market
2. Mount Sinai & ENT and Allergy Associates, LLP affiliate to fight cancer
3. Paramount Acquisition Corp. Announces Record Date of October 1, 2007 for Proposed Acquisition of Chem Rx
4. Kaiser Permanente study: Alcohol amount, not type -- wine, beer, liquor -- triggers breast cancer
5. Paramount Acquisition Corp. Files Amendment to Preliminary Proxy Statement for Proposed Acquisition of Chem Rx
6. Fred Hutchinson Cancer Research Center Announces the First-Ever Expedition to an Unclimbed Mountain in the Name of Cancer Research
7. Iron Mountain Acquires RMS Services - USA, Inc.
8. Surge in U.S. Cases of Rocky Mountain Spotted Fever
9. Oregon Scientific to Sponsor First-Ever Rock Concert on Mount Everest
10. Mount Sinai recognized as Center of Excellence for Research in Alzheimers disease
11. Paramount Completes Acquisition of Chem Rx
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/24/2017)... ... January 23, 2017 , ... The TouchPoint Solution, ... who entered metrics into the product’s app. The data replicates and validates ... that within just 30 seconds of using Buzzies, people experienced a 74 percent ...
(Date:1/24/2017)... ... January 23, 2017 , ... ... a new plugin that allows sleep centers to automatically connect and initialize all ... a thin client browser plugin is quickly installed on first use and then ...
(Date:1/23/2017)... ... January 23, 2017 , ... ... week at a new domain address. Alpine Springs Rehabilitation & Recovery Center’s new ... debuted a new logo along with its redesigned and retooled website. The treatment ...
(Date:1/23/2017)... Palo Alto, CA (PRWEB) , ... ... ... Translations, a provider of translation and localization services for life science companies, ... testing and inspection organization, TÜV SÜD America. ISO 17100 is the globally ...
(Date:1/23/2017)... ... January 23, 2017 , ... DMG ... Innovations with Ed Begley, Jr., scheduled to broadcast Saturday, January 28, 2017 at ... was founded in 2008 to address the limitations of fatigue monitoring technologies within ...
Breaking Medicine News(10 mins):
(Date:1/23/2017)... 23, 2017  Allergan plc, (NYSE: AGN ), ... of the International Headache Academy (IHA). Designed to inspire a ... scientists, IHA offers a three-day, intensive overview on research and ... been the sole sponsor since the inception of IHA in ... in Europe in 2014. ...
(Date:1/23/2017)...  Using Astute Medical,s NephroCheck Test ... kidney injury (AKI) after open-heart surgery and providing ... significantly improved outcomes by reducing the occurrence ... percent, according to a study published ... Medicine. Experience the interactive Multimedia ...
(Date:1/23/2017)... YORK , January 23, 2017 ... Catalyst Pharmaceuticals Inc. (NASDAQ: CPRX ), Sophiris Bio ... MNTA ), and Agile Therapeutics Inc. (NASDAQ: ... sector which turned somewhat lower in late trade on Friday, ... Index dropping about 0.3%, while shares of health care companies ...
Breaking Medicine Technology: